DRIZALMA SPRINKLE

Peak

duloxetine

NDAORALCAPSULE, DELAYED REL PELLETS
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.

Clinical Trials (5)

NCT04388189Phase 4Withdrawn

Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion

Started Oct 2020
0
Major Depressive Disorder
NCT04137107Phase 2/3Active Not Recruiting

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Started Jun 2020
220 enrolled
Stage II Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8
NCT03729284Phase 4Withdrawn

A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta

Started Mar 2020
0
Healthy
NCT03794154Phase 4Withdrawn

A Study Of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta Under Fed Conditions

Started Mar 2020
0
Healthy
NCT03395353Phase 3Terminated

A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder

Started Jan 2018
151 enrolled
Depressive Disorder

Loss of Exclusivity

LOE Date
Apr 13, 2037
135 months away
Patent Expiry
Apr 13, 2037

Patent Records (5)

Patent #ExpiryTypeUse Code
10413525
Apr 13, 2037
Product
10959982
Apr 13, 2037
Product
11202772
Apr 13, 2037
Product
12171742
Apr 13, 2037
Product
9839626
Apr 13, 2037
Product